Apart from defining the expectations for FSPs (functional service providers), the pharma industry’s use of SLAs (service level agreements) has not been commonplace despite the tangible benefits these documents offer. In essence, the SLA defines critical metrics and levels of expectations for service, as well as outlines incentives and disincentives for meeting/missing those metrics and expectations.
But to avoid disputes between the two parties, it is essential that the expected level of service be clearly defined for each service provider in writing prior to initiating work.
START BY DEFINING METRICS
The initial conversation with a service provider should include a discussion of the metrics deemed critical to the success of the outsourced program or service. Those metrics should reflect your business requirements, be economical to measure (e.g., calculate performance) and report, and be simple to understand. Regarding the latter, everyone should agree that what needs to be measured can be easily written down. The Everest Group suggests following the acronym SMART when defining performance metrics:
Of course, for any outsourced program to succeed, you must have explicit endorsement (either active or vocal participation) of senior management and decision makers within each organization.
AVOID COMMON PITFALLS
When defining what is acceptable regarding your SLA, beware of pitfalls such as expecting more of your service provider than you may expect of your own staff or driving toward perfection. While these may be valid goals, you must bear in mind the inherent cost of each position. For example, if your internal team states it is critical for them to have final monitoring trip reports to review within five business days after the visit, that may not be the SOP timeline for the service provider. Therefore, your internal team needs to establish reasonable expected service levels and see how those expectations line up with the service provider’s capabilities.
Ultimately, you need to gain trust to put this type of agreement in place. To do so, have governance meetings on a regular basis and ad hoc discussions as needed. For any of these meetings, develop agendas, take detailed minutes, track follow-up items, and have someone in charge of delegating. Doing so ensures these discussions progress rather than becoming a time burden on an already busy workforce.
THREE SLA MODELS
In our experience, it is advantageous to incentivize your service providers to meet or exceed your expected performance levels. While global CROs may have experience with performance metric regimes, the SLA framework can still be far from standard and generally requires tailored solutions. The following are three examples of models we have utilized during our careers.
"It is essential that the expected level of service be clearly defined for each service provider in writing prior to initiating work."
SLAs ARE MUTUALLY BENEFICIAL
In reality, it is not in anyone’s best interest to apply disincentives when the agreedupon service levels are missed. The sponsor needs the service provider to deliver on its commitments, while the service provider needs a clear view of the sponsor’s expectations and expected revenue from each program. In summary, SLAs provide a framework and structure for:
Debbie Dwyer is associate director of clinical outsourcing at Nektar Therapeutics. She has more than 20 years’ experience in clinical operations and outsourcing.
With 25 years’ drug development experience, Jonathan Lee is currently VP of development operations at Cidara Therapeutics focusing on antifungal therapies.